

CITY OF LOS ANGELES

CALIFORNIA



ERIC GARCETTI
MAYOR

Office of the
CITY CLERK

Council and Public Services
Room 395, City Hall
Los Angeles, CA 90012
General Information - (213) 978-1133
Fax: (213) 978-1040

SHANNON HOPPES
Council and Public Services
Division

www.cityclerk.lacity.org

HOLLY L. WOLCOTT
Interim City Clerk

When making inquiries relative to
this matter, please refer to the
Council File No.

June 17, 2014

To All Interested Parties:

Chief Legislative Analyst

I HEREBY CERTIFY that the City Council adopted the action(s), as attached, under
Council File No. 14-0002-S45, at its meeting held June 4, 2014.

City Clerk
wrq

cc: 8 Certified copies sent to Washington Representatives

Mayor's Time Stamp
2014 JUN -6 PM 3:31
CITY OF LOS ANGELES

FORTHWITH

City Clerk's Time Stamp
CITY CLERK'S OFFICE
2014 JUN -6 PM 3:34
CITY CLERK
BY _____ DEPUTY

SUBJECT TO THE CONCURRENCE OF THE MAYOR

COUNCIL FILE NO. 14-0002-S45

COUNCIL DISTRICT _____

COUNCIL APPROVAL DATE June 4, 2014

RE: ESTABLISHING THE CITY'S POSITION TO SUPPORT RESEARCH TO DEVELOP A PHARMACEUTICAL VERSION OF A CANNABIS EXTRACT

LAST DAY FOR MAYOR TO ACT JUN 16 2014
[10 Day Charter requirement as per Charter Section 231(h)]

DO NOT WRITE BELOW THIS LINE - FOR MAYOR USE ONLY

APPROVED

✓

*DISAPPROVED

*Transmit objections in writing pursuant to Charter Section 231 (h)

DATE OF MAYOR APPROVAL OR DISAPPROVAL 6/16/14

E. G. [Signature]
MAYOR

RECEIVED
CITY CLERK'S OFFICE
2014 JUN 16 PM 3:35
CITY CLERK
BY _____ DEPUTY

15

RULES, ELECTIONS AND INTERGOVERNMENTAL RELATIONS COMMITTEE REPORT and RESOLUTION relative to establishing the City's position to support research to develop a pharmaceutical version of a cannabis extract.

Recommendation for Council action, pursuant to Resolution (Parks - Koretz), SUBJECT TO THE CONCURRENCE OF THE MAYOR:

ADOPT the accompanying RESOLUTION to include in the City's 2013-14 Federal Legislative Program SUPPORT for any administrative action which would have the Food and Drug Administration (FDA) support pending research to develop a pharmaceutical version of a cannabis extract to treat epilepsy and to select the University of California, Los Angeles (UCLA) as one of the permitted sites to test this product.

Fiscal Impact Statement: None submitted by the Chief Legislative Analyst (CLA). The City Administrative Officer has not completed a financial analysis of this report.

Community Impact Statement: None submitted.

Summary:

At its regular meeting of May 16, 2014, the Rules, Elections and Intergovernmental Relations Committee considered a CLA report and Resolution (Parks - Koretz) relative to establishing the City's position to support research to develop a pharmaceutical version of a cannabis extract. The CLA report, attached to the Council file, provides a summary of the Resolution and additional background information. After consideration and having provided an opportunity for public comment, the Committee recommended that Council adopt the accompanying Resolution. This matter is now submitted to Council for its consideration.

Respectfully Submitted,

RULES, ELECTIONS AND INTERGOVERNMENTAL RELATIONS COMMITTEE



MEMBER VOTE

WESSON: YES

HUIZAR: ABSENT

LABONGE: YES

ADOPTED

JUN 0 4 2014

LOS ANGELES CITY COUNCIL

ep
14-0002-S45_rpt_reir_5-16-14

**TO THE MAYOR FORTHWITH
-NOT OFFICIAL UNTIL COUNCIL ACTS-**

14-0002-545

APR 11 2014

RESOLUTION

RULE, ACTIONS & INTERGOVERNMENTAL RELATIONS

WHEREAS, any official position of the City of Los Angeles with respect to legislation, rules, regulations or policies proposed to or pending before a local, state or federal governmental body or agency must have first been adopted in the form of a Resolution by the City Council with the concurrence of the Mayor; and

WHEREAS, a British company developing a pharmaceutical version of a cannabis extract used to treat epilepsy could be allowed to test its product at UCLA as part of the Food and Drug Administration approval process; and

WHEREAS, United Kingdom-based GW Pharmaceuticals received the approval to continue with clinical trials for their product Epidiolex in February and UCLA wants to be on the list of test sites; and

WHEREAS, the pharmaceutical company is willing to sponsor a small series of patients at half a dozen centers, but they are waiting for clearance by the federal Food and Drug Administration (FDA); and

WHEREAS, Epidiolex will use high concentrations of cannabidiol, a compound found in marijuana, to try to reduce seizures for patients with severe epilepsy, namely children with Dravet's syndrome or Lennox-Gastaut syndrome; and

WHEREAS, as a participant, UCLA would treat a small number of patients with Epidiolex and record the results; if the data from UCLA and other test sites is encouraging, GW Pharmaceuticals will move onto the next step in the FDA approval process; and

WHEREAS, UCLA's research center will have to pass an inspection from the Drug Enforcement Administration because of the federal government's classification of marijuana as a Schedule I drug; and

WHEREAS, some parents in states with medical marijuana programs have found success using existing products found in dispensaries; and

WHEREAS, this would be the first time that the correct approach is being followed, especially through the federal government, to declare a marijuana derived substances as legitimate medicine;

NOW, THEREFORE, BE IT RESOLVED, with the concurrence of the Mayor, that by the adoption of this Resolution, the City of Los Angeles hereby includes in its 2013-2014 Federal Legislative Program support for any administrative action which would have the Food and Drug Administration (FDA) support pending research to develop a pharmaceutical version of a cannabis extract used to treat epilepsy and to select UCLA as one of the permitted sites to test this product.

ADOPTED

JUN 04 2014

LOS ANGELES CITY COUNCIL

ak TO THE MAYOR FORTHWITH

PRESENTED BY:

Bernard C. Parks
BERNARD C. PARKS
Councilman, 8th District

SECONDED BY:

Paul Krejci

ORIGINAL

APR 11 2014